drugset / Trial / NCT04299633

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

NCT04299633

Phase 1 Completed 54 enrolled Akebia Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

This 3-part study will be conducted to evaluate the interaction of vadadustat with sevelamer carbonate, calcium acetate, and Auryxia in healthy male and female participants. A total of 18 participants will be enrolled in each part of the study. Part 1 of the study will be conducted to assess the effect of a single oral dose of sevelamer carbonate (1600 milligrams \[mg\]) on the pharmacokinetics (PK) of a single oral dose of vadadustat (300 mg). Part 2 of the study will be conducted to assess the effect of a single oral dose of calcium acetate (1334 mg) on the PK of a single oral dose of vadadustat (300 mg). Part 3 of the study will be conducted to assess the effect of a single oral dose of Auryxia® (2 grams) on the PK of a single oral dose of vadadustat (300 mg).

Timeline

Start
2020-06-15
Primary completion
2020-08-02
Completion
2020-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium carbonate Other / unclassified 1334 mg Oral
Subject KRX-0502 Small molecule 2 g Oral
Subject Vadadustat Small molecule 300 mg Oral
Subject sevelamer Other / unclassified 1600 mg Oral

Indications

No indication recorded.